RZLT.O (RZLT.O) News
Follow RZLT.O (RZLT.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism
Oct 14 (Reuters) — Rezolute, Inc.: Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism Rezolute - Completes Enrollment In Phase 3 Uplift Study; Topline Results Expect
CENTRAL_BANK | Oct 14, 2026, 09:04 PM UTC
L
Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism
Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism. Topline results are expected in mid-December 2026. * Previously reported results showed seven of the fi
NEWS | Oct 14, 2026, 08:11 PM UTC